Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy ; volume:271 ; number:10 ; day:6 ; month:9 ; year:2024 ; pages:7000-7011 ; date:10.2024
Journal of neurology ; 271, Heft 10 (6.9.2024), 7000-7011, 10.2024
- Urheber
-
Dobelmann, Vera
Roos, Andreas
Hentschel, Andreas
Della Marina, Adela
Leo, Markus
Schmitt, Linda-Isabell
Maggi, Lorenzo
Schara-Schmidt, Ulrike
Hagenacker, Tim
Ruck, Tobias
Kölbel, Heike
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00415-024-12670-0
- URN
-
urn:nbn:de:101:1-2412192155395.025009168158
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dobelmann, Vera
- Roos, Andreas
- Hentschel, Andreas
- Della Marina, Adela
- Leo, Markus
- Schmitt, Linda-Isabell
- Maggi, Lorenzo
- Schara-Schmidt, Ulrike
- Hagenacker, Tim
- Ruck, Tobias
- Kölbel, Heike
- SpringerLink (Online service)
Ähnliche Objekte (12)
Spinal muscular atrophy
Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy
Dysregulation of cerebrospinal fluid metabolism profiles in spinal muscular atrophy patients: a case control study
Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen
Muscle contractility in spinobulbar muscular atrophy
Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy
Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges
Very severe spinal muscular atrophy (Type 0)
A cross-sectional and longitudinal evaluation of serum creatinine as a biomarker in spinal muscular atrophy
Disease burden of spinal muscular atrophy in Germany
Choosing Life with Spinal Muscular Atrophy Type 1
Therapeutic advances in 5q-linked spinal muscular atrophy
Spinal muscular atrophy
Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy
Dysregulation of cerebrospinal fluid metabolism profiles in spinal muscular atrophy patients: a case control study
Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen
Muscle contractility in spinobulbar muscular atrophy
Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy
Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges
Very severe spinal muscular atrophy (Type 0)
A cross-sectional and longitudinal evaluation of serum creatinine as a biomarker in spinal muscular atrophy
Disease burden of spinal muscular atrophy in Germany
Choosing Life with Spinal Muscular Atrophy Type 1
Therapeutic advances in 5q-linked spinal muscular atrophy
Spinal muscular atrophy
Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy
Dysregulation of cerebrospinal fluid metabolism profiles in spinal muscular atrophy patients: a case control study
Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen
Muscle contractility in spinobulbar muscular atrophy
Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy
Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges
Very severe spinal muscular atrophy (Type 0)
A cross-sectional and longitudinal evaluation of serum creatinine as a biomarker in spinal muscular atrophy
Disease burden of spinal muscular atrophy in Germany
Choosing Life with Spinal Muscular Atrophy Type 1